Trials / Completed
CompletedNCT01693315
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Amakem, NV · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMA0076 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2012-09-26
- Last updated
- 2013-07-17
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01693315. Inclusion in this directory is not an endorsement.